PriceTargets.com logo

NASDAQ:IRTC - iRhythm Technologies Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $217.25
  • Forecasted Upside: 41.99 %
  • Number of Analysts: 11
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 8 Buy Ratings
  • 0 Strong Buy Ratings
$153.00 As of 02/24/2021 01:00 AM ET
▼ -2.46 (-1.58%)
1 month | 3 months | 12 months
Get New iRhythm Technologies Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IRTC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IRTC

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$217.25
▲ +41.99% Upside Potential
This price target is based on 11 analysts offering 12 month price targets for iRhythm Technologies in the last 3 months. The average price target is $217.25, with a high forecast of $288.00 and a low forecast of $130.00. The average price target represents a 41.99% upside from the last price of $153.00.
Buy
The current consensus among 11 contributing investment analysts is to buy stock in iRhythm Technologies. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
9/3/2019
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
12/2/2019
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/1/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/30/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/28/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
11/26/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
1/25/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
2/24/2021

Latest Recommendations

  • 0 strong buy ratings
  • 8 buy ratings
  • 3 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/4/2021BTIG ResearchLower Price TargetBuy$283.00 ➝ $210.00Low
i
2/1/2021TruistLower Price Target$265.00 ➝ $220.00Low
i
1/29/2021Needham & Company LLCReiterated RatingHoldHigh
i
1/25/2021Morgan StanleyBoost Price TargetOverweight$227.00 ➝ $288.00High
i
1/21/2021BTIG ResearchBoost Price TargetBuy$235.00 ➝ $283.00High
i
12/15/2020Morgan StanleyLower Price TargetOverweight$230.00 ➝ $227.00High
i
12/10/2020William BlairReiterated RatingBuyMedium
i
12/3/2020Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellLower Price Target$275.00 ➝ $238.00High
i
12/3/2020TruistLower Price Target$265.00 ➝ $240.00Medium
i
12/3/2020Smith Barney CitigroupLower Price Target$275.00 ➝ $238.00Medium
i
12/3/2020Robert W. BairdLower Price TargetNeutral$220.00 ➝ $170.00High
i
12/2/2020Morgan StanleyLower Price TargetOverweight$270.00 ➝ $230.00High
i
11/17/2020OppenheimerDowngradeOutperform ➝ Market PerformHigh
i
11/17/2020Needham & Company LLCReiterated RatingHoldHigh
i
11/6/2020TruistBoost Price Target$200.00 ➝ $265.00Low
i
11/6/2020Morgan StanleyBoost Price TargetOverweight$259.00 ➝ $270.00Low
i
11/6/2020Canaccord GenuityBoost Price TargetBuy$236.00 ➝ $273.00Medium
i
11/6/2020OppenheimerReiterated RatingBuy$200.00 ➝ $250.00High
i
10/12/2020BTIG ResearchBoost Price Target$130.00 ➝ $160.00Low
i
9/11/2020Needham & Company LLCInitiated CoverageHoldLow
i
9/1/2020Robert W. BairdInitiated CoverageNeutral$220.00Medium
i
8/26/2020Canaccord GenuityBoost Price TargetBuy$210.00 ➝ $236.00Low
i
8/25/2020CitigroupBoost Price TargetBuy$215.00 ➝ $250.00Low
i
8/7/2020Colliers SecuritiesUpgradeNeutral ➝ Buy$200.00High
i
Rating by G. Mannheimer at Colliers Securities
8/5/2020Canaccord GenuityBoost Price TargetPositive ➝ Buy$130.00 ➝ $189.00High
i
8/5/2020CitigroupBoost Price TargetBuy$147.00 ➝ $200.00High
i
8/5/2020OppenheimerUpgradeMarket Perform ➝ Outperform$200.00High
i
5/8/2020JPMorgan Chase & Co.Boost Price TargetOverweight$125.00 ➝ $140.00Low
i
5/8/2020Morgan StanleyBoost Price TargetOverweight$114.00 ➝ $142.00Low
i
5/8/2020SunTrust BanksBoost Price TargetBuy$102.00 ➝ $130.00High
i
5/8/2020Canaccord GenuityBoost Price TargetBuy$107.00 ➝ $130.00High
i
Rating by Jason Mills at Canaccord Genuity
5/8/2020BTIG ResearchReiterated RatingBuy$130.00High
i
Rating by Marie Thibault at BTIG Research
5/8/2020OppenheimerReiterated RatingHoldHigh
i
4/13/2020Canaccord GenuityLower Price TargetBuy$112.00 ➝ $107.00High
i
Rating by Jason Mills at Canaccord Genuity
3/27/2020Morgan StanleyBoost Price TargetOverweight$110.00 ➝ $114.00High
i
3/27/2020CitigroupLower Price TargetBuy$120.00 ➝ $112.00High
i
3/4/2020CitigroupInitiated CoverageBuy$120.00Medium
i
2/28/2020Canaccord GenuityBoost Price TargetBuy$107.00 ➝ $112.00Medium
i
Rating by Jason Mills at Canaccord Genuity
2/5/2020BTIG ResearchInitiated CoverageBuy$90.00Low
i
Rating by Marie Thibault at BTIG Research
1/9/2020William BlairInitiated CoverageOutperformHigh
i
Rating by M. Kaczor at William Blair
1/7/2020SunTrust BanksInitiated CoverageBuy$102.00High
i
12/24/2019Canaccord GenuityReiterated RatingBuy$107.00Low
i
Rating by Jason Mills at Canaccord Genuity
12/17/2019Morgan StanleyBoost Price TargetOverweight$101.00 ➝ $110.00Low
i
10/22/2019OppenheimerInitiated CoverageMarket PerformLow
i
8/1/2019JPMorgan Chase & Co.Boost Price TargetOverweight$110.00 ➝ $125.00High
i
7/31/2019BTIG ResearchSet Price TargetBuy$90.00N/A
i
Rating by Sean Lavin at BTIG Research
5/8/2019BTIG ResearchBoost Price TargetPositive ➝ Buy$90.00High
i
4/3/2019BTIG ResearchUpgradeNeutral ➝ Buy$80.00Medium
i
2/20/2019Chardan CapitalDowngradeBuy ➝ Neutral$111.00 ➝ $104.00Low
i
2/13/2019Royal Bank of CanadaBoost Price TargetOutperform$109.00Low
i
2/13/2019JPMorgan Chase & Co.Boost Price Target$110.00Low
i
2/13/2019Morgan StanleyBoost Price TargetOverweight ➝ Overweight$85.00 ➝ $101.00Medium
i
2/13/2019Northland SecuritiesReiterated RatingHold$75.00High
i
2/13/2019BTIG ResearchReiterated RatingHoldMedium
i
2/13/2019BMO Capital MarketsBoost Price TargetOutperform ➝ Outperform$96.00 ➝ $105.00High
i
2/13/2019Canaccord GenuityBoost Price TargetBuy ➝ Buy$90.00 ➝ $104.00High
i
1/11/2019Canaccord GenuityBoost Price TargetBuy ➝ Buy$84.00 ➝ $90.00Low
i
10/11/2018Morgan StanleyBoost Price TargetOverweight$92.00 ➝ $95.00High
i
9/13/2018Canaccord GenuityBoost Price TargetBuy ➝ Buy$93.00 ➝ $100.00Low
i
9/6/2018Chardan CapitalInitiated CoverageBuy ➝ Buy$117.00Medium
i
8/2/2018Dougherty & CoUpgradeSell ➝ NeutralHigh
i
Rating by G. Mannheimer at Dougherty & Co
8/2/2018BTIG ResearchReiterated RatingHoldHigh
i
8/2/2018Morgan StanleyBoost Price TargetOverweight ➝ Overweight$86.00 ➝ $92.00High
i
8/2/2018JPMorgan Chase & Co.Reiterated RatingOverweight$100.00High
i
8/2/2018Canaccord GenuityReiterated RatingBuy$93.00High
i
8/2/2018BMO Capital MarketsBoost Price TargetOutperform ➝ Outperform$93.00 ➝ $96.00High
i
7/16/2018Dougherty & CoDowngradeNeutral ➝ SellMedium
i
Rating by G. Mannheimer at Dougherty & Co
7/10/2018BMO Capital MarketsBoost Price TargetOutperform$93.00High
i
6/13/2018Royal Bank of CanadaBoost Price TargetOutperform$91.00Medium
i
6/4/2018Morgan StanleyBoost Price TargetOverweight ➝ Overweight$70.00 ➝ $86.00Low
i
4/16/2018Northland SecuritiesReiterated RatingHold$60.00Low
i
3/14/2018Northland SecuritiesReiterated RatingHold$60.00Low
i
3/12/2018Canaccord GenuityReiterated RatingBuy ➝ Buy$68.00 ➝ $80.00Low
i
3/5/2018BMO Capital MarketsInitiated CoverageOutperform$76.00Medium
i
2/15/2018JPMorgan Chase & Co.Boost Price TargetOverweight ➝ Overweight$62.00 ➝ $67.00High
i
12/4/2017Royal Bank of CanadaInitiated CoverageOutperform$79.00High
i
12/1/2017Dougherty & CoInitiated CoverageNeutral ➝ NeutralMedium
i
Rating by G. Mannheimer at Dougherty & Co
11/14/2017Canaccord GenuityReiterated RatingBuy$59.00N/A
i
11/3/2017Morgan StanleyBoost Price TargetOverweight$50.00 ➝ $65.00N/A
i
11/2/2017Canaccord GenuityBoost Price TargetBuy$55.00 ➝ $59.00N/A
i
9/22/2017Canaccord GenuityBoost Price TargetBuy$49.00 ➝ $55.00High
i
6/6/2017Canaccord GenuityReiterated RatingBuy$42.00Medium
i
6/6/2017Morgan StanleyBoost Price TargetOverweight$43.00 ➝ $47.00High
i
5/15/2017Canaccord GenuityReiterated RatingBuy$42.00N/A
i
5/5/2017Canaccord GenuityReiterated RatingBuy$42.00Low
i
Rating by Jason Mills at Canaccord Genuity
4/10/2017Canaccord GenuityReiterated RatingBuy$40.00Low
i
Rating by Jason Mills at Canaccord Genuity
12/6/2016BTIG ResearchDowngradeBuy ➝ NeutralN/A
i
11/14/2016Morgan StanleyInitiated CoverageOverweight$28.00N/A
i
11/14/2016Canaccord GenuityInitiated CoverageBuy$31.00N/A
i
11/14/2016BTIG ResearchInitiated CoverageBuy$28.00N/A
i
11/14/2016JPMorgan Chase & Co.Initiated CoverageOverweight$34.00N/A
i
(Data available from 2/25/2016 forward)
iRhythm Technologies logo
iRhythm Technologies, Inc., a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. It offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-based, and wearable biosensor with a cloud-based data analytic platform to help physicians to monitor patients and diagnose arrhythmias. The company's Zio XT and AT monitors, a single-use, wire-free, and wearable patch-based biosensors, records patient's heartbeats and ECG data. It has a development collaboration agreement with Verily Life Sciences LLC to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was founded in 2006 and is headquartered in San Francisco, California.
Read More

Today's Range

Now: $153.00
$152.71
$159.49

50 Day Range

MA: $206.02
$155.46
$268.46

52 Week Range

Now: $153.00
$56.54
$286.19

Volume

484,092 shs

Average Volume

677,429 shs

Market Capitalization

$4.42 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.68

Frequently Asked Questions

What sell-side analysts currently cover shares of iRhythm Technologies?

The following Wall Street sell-side analysts have issued research reports on iRhythm Technologies in the last twelve months: BTIG Research, Canaccord Genuity, Citigroup Inc., Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell, Colliers Securities, JPMorgan Chase & Co., Morgan Stanley, Needham & Company LLC, Oppenheimer Holdings Inc., Robert W. Baird, Smith Barney Citigroup, SunTrust Banks, Inc., TheStreet, Truist, William Blair, and Zacks Investment Research.
View the latest analyst ratings for IRTC.

What is the current price target for iRhythm Technologies?

12 Wall Street analysts have set twelve-month price targets for iRhythm Technologies in the last year. Their average twelve-month price target is $217.25, suggesting a possible upside of 39.7%. Morgan Stanley has the highest price target set, predicting IRTC will reach $288.00 in the next twelve months. SunTrust Banks, Inc. has the lowest price target set, forecasting a price of $130.00 for iRhythm Technologies in the next year.
View the latest price targets for IRTC.

What is the current consensus analyst rating for iRhythm Technologies?

iRhythm Technologies currently has 3 hold ratings and 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe IRTC will outperform the market and that investors should add to their positions of iRhythm Technologies.
View the latest ratings for IRTC.

What other companies compete with iRhythm Technologies?

Other companies that are similar to iRhythm Technologies include NovoCure, Insulet, Abiomed, Penumbra, Hill-Rom, Haemonetics, Globus Medical, Inspire Medical Systems, Integra LifeSciences, Nevro, Tandem Diabetes Care, Inari Medical, ICU Medical, Glaukos and ShockWave Medical.

How do I contact iRhythm Technologies' investor relations team?

iRhythm Technologies' physical mailing address is 650 TOWNSEND STREET SUITE 500, San Francisco CA, 94103. The company's listed phone number is 415-632-5700 and its investor relations email address is [email protected] The official website for iRhythm Technologies is www.irhythmtech.com.